{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:56:09Z","timestamp":1778154969421,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1053\/j.ajkd.2012.01.027","type":"journal-article","created":{"date-parts":[[2012,4,20]],"date-time":"2012-04-20T13:59:56Z","timestamp":1334930396000},"page":"308-315","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Long-term Management of CKD\u2013Mineral and Bone Disorder"],"prefix":"10.1053","volume":"60","author":[{"given":"Kevin J.","family":"Martin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther A.","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1053\/j.ajkd.2012.01.027_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/j.ackd.2006.10.005","article-title":"Chronic kidney disease-mineral-bone disorder: a new paradigm","volume":"14","author":"Moe","year":"2007","journal-title":"Adv Chronic Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2012.01.027_bib2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1681\/ASN.2006070771","article-title":"Metabolic bone disease in chronic kidney disease","volume":"18","author":"Martin","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2012.01.027_bib3","first-page":"F1577","article-title":"Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro","volume":"293","author":"Perwad","year":"2007","journal-title":"Am J Physiol"},{"issue":"3","key":"10.1053\/j.ajkd.2012.01.027_bib4","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1359\/JBMR.0301264","article-title":"FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis","volume":"19","author":"Shimada","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib5","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0092-8674(00)80655-8","article-title":"An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3","volume":"96","author":"Nykjaer","year":"1999","journal-title":"Cell"},{"issue":"11","key":"10.1053\/j.ajkd.2012.01.027_bib6","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/sj.ki.5002532","article-title":"Parathyroid hormone fragments inhibit active hormone and hypocalcemia-induced 1,25(OH)2D synthesis","volume":"72","author":"Usatii","year":"2007","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2012.01.027_bib7","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/ki.1972.84","article-title":"On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using \u201cproportional reduction\u201d of dietary phosphorus intake","volume":"2","author":"Slatopolsky","year":"1972","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2012.01.027_bib8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1172\/JCI106517","article-title":"On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog","volume":"50","author":"Slatopolsky","year":"1971","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1053\/j.ajkd.2012.01.027_bib9","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ki.2011.47","article-title":"Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease","volume":"79","author":"Isakova","year":"2011","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2012.01.027_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","article-title":"Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD","volume":"50","author":"Al-Aly","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2012.01.027_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease","volume":"27","author":"Zisman","year":"2007","journal-title":"Am J Nephrol"},{"issue":"suppl 3","key":"10.1053\/j.ajkd.2012.01.027_bib12","first-page":"S1","article-title":"K\/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease","volume":"42(4)","year":"2003","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 113","key":"10.1053\/j.ajkd.2012.01.027_bib13","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"76","year":"2009","journal-title":"Kidney Int"},{"issue":"10","key":"10.1053\/j.ajkd.2012.01.027_bib14","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s00467-007-0508-0","article-title":"Parathyroid hormone assay: problems and opportunities","volume":"22","author":"Martin","year":"2007","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2012.01.027_bib15","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.ki.5001606","article-title":"Inter-method variability in PTH measurement: implication for the care of CKD patients","volume":"70","author":"Souberbielle","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2012.01.027_bib16","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1093\/ndt\/gfq219","article-title":"Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population","volume":"26","author":"Floege","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/sj.ki.5001514","article-title":"Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients","volume":"70","author":"Kalantar-Zadeh","year":"2006","journal-title":"Kidney Int"},{"issue":"6","key":"10.1053\/j.ajkd.2012.01.027_bib18","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/ndt\/gfq304","article-title":"Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America","volume":"26","author":"Naves-Diaz","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2012.01.027_bib19","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1053\/j.ajkd.2011.07.020","article-title":"The role of phosphorus in the development and progression of vascular calcification","volume":"58","author":"Kendrick","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2012.01.027_bib20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.bone.2009.09.006","article-title":"High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression","volume":"46","author":"Roman-Garcia","year":"2010","journal-title":"Bone"},{"issue":"6","key":"10.1053\/j.ajkd.2012.01.027_bib21","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00467-011-1822-0","article-title":"Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients","volume":"26","author":"Srivaths","year":"2011","journal-title":"Pediatr Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1053\/ajkd.1998.v31.pm9531176","article-title":"Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study","volume":"31","author":"Block","year":"1998","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib23","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1111\/j.1523-1755.2005.00600.x","article-title":"Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis","volume":"68","author":"Block","year":"2005","journal-title":"Kidney Int"},{"issue":"1","key":"10.1053\/j.ajkd.2012.01.027_bib24","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","article-title":"Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients","volume":"62","author":"Chertow","year":"2002","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib25","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1053\/j.ajkd.2009.06.004","article-title":"Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials","volume":"54","author":"Navaneethan","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2012.01.027_bib26","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1053\/j.ajkd.2008.02.298","article-title":"A 1-year randomized trial of calcium acetate versus sevelamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calcium Acetate Renagel Evaluation-2 (CARE-2) Study","volume":"51","author":"Qunibi","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib27","doi-asserted-by":"crossref","first-page":"c273","DOI":"10.1159\/000170783","article-title":"Phosphate binder impact on bone remodeling and coronary calcification\u2014results from the BRiC Study","volume":"110","author":"Barreto","year":"2008","journal-title":"Nephron Clin Pract"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib28","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1161\/hy1001.096358","article-title":"Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease","volume":"38","author":"Blacher","year":"2001","journal-title":"Hypertension"},{"issue":"9","key":"10.1053\/j.ajkd.2012.01.027_bib29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.ki.5002466","article-title":"Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients","volume":"72","author":"Suki","year":"2007","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2012.01.027_bib30","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/sj.ki.5002059","article-title":"Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients","volume":"71","author":"Block","year":"2007","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib31","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/archinternmed.2007.110","article-title":"Association of activated vitamin D treatment and mortality in chronic kidney disease","volume":"168","author":"Kovesdy","year":"2008","journal-title":"Arch Intern Med"},{"issue":"8","key":"10.1053\/j.ajkd.2012.01.027_bib32","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1681\/ASN.2007111164","article-title":"Association of oral calcitriol with improved survival in nondialyzed CKD","volume":"19","author":"Shoben","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2012.01.027_bib33","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","article-title":"Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy","volume":"349","author":"Teng","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib34","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","article-title":"Activated injectable vitamin D and hemodialysis survival: a historical cohort study","volume":"16","author":"Teng","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ajkd.2012.01.027_bib35","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/ndt\/gfn592","article-title":"The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study","volume":"24","author":"Tentori","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1053\/j.ajkd.2012.01.027_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1525-139X.2009.00566.x","article-title":"When is vitamin D contraindicated in dialysis patients?","volume":"22","author":"Martin","year":"2009","journal-title":"Semin Dial"},{"issue":"6","key":"10.1053\/j.ajkd.2012.01.027_bib37","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/sj.ki.5002406","article-title":"Differential effects of vitamin D receptor activators on vascular calcification in uremic rats","volume":"72","author":"Mizobuchi","year":"2007","journal-title":"Kidney Int"},{"issue":"8","key":"10.1053\/j.ajkd.2012.01.027_bib38","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2012.01.027_bib39","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/ki.2008.101","article-title":"Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice","volume":"74","author":"Zhou","year":"2008","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2012.01.027_bib40","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.06510909","article-title":"Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters","volume":"5","author":"Matias","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"15","key":"10.1053\/j.ajkd.2012.01.027_bib41","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1056\/NEJMoa031633","article-title":"Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis","volume":"350","author":"Block","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2012.01.027_bib42","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1523-1755.2005.67139.x","article-title":"Achieving NKF-K\/DOQI bone metabolism and disease treatment goals with cinacalcet HCl","volume":"67","author":"Moe","year":"2005","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2012.01.027_bib43","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1053\/j.ajkd.2012.01.027_bib44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1542-4758.2009.00397.x","article-title":"Assessment of adherence to cinacalcet by prescription refill rates in hemodialysis patients","volume":"14","author":"Gincherman","year":"2010","journal-title":"Hemodial Int"},{"issue":"6","key":"10.1053\/j.ajkd.2012.01.027_bib45","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Gutierrez","year":"2008","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2012.01.027_bib46","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1093\/ndt\/gfp191","article-title":"High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"issue":"23","key":"10.1053\/j.ajkd.2012.01.027_bib47","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"Jama"},{"issue":"11","key":"10.1053\/j.ajkd.2012.01.027_bib48","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1053\/j.ajkd.2012.01.027_bib49","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","article-title":"Effects of cinacalcet and concurrent low-dose vitamin D on FGF-23 levels in ESRD","volume":"5","author":"Wetmore","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2012.01.027_bib50","doi-asserted-by":"crossref","first-page":"440","DOI":"10.2215\/CJN.05130610","article-title":"Prevention and control of phosphate retention\/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?","volume":"6","author":"Martin","year":"2011","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638612005574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638612005574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:58:30Z","timestamp":1759456710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638612005574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":50,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0272638612005574"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2012.01.027","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Management of CKD\u2013Mineral and Bone Disorder","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2012.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}